It has been shown that upregulation of IGF2 drives chemoresistance to Taxol (paclitaxel), fluorouracil and CDDP, in ovarian cancer [70,71], esophageal cancer [72], and HNC [73], respectively. This evidence concerns the gene IGF2 and ovarian cancer.